TY - JOUR T1 - De novo variants in the <em>PSMC3</em> proteasome AAA-ATPase subunit gene cause neurodevelopmental disorders associated with type I interferonopathies JF - medRxiv DO - 10.1101/2021.12.07.21266342 SP - 2021.12.07.21266342 AU - Frédéric Ebstein AU - Sébastien Küry AU - Victoria Most AU - Cory Rosenfelt AU - Marie-Pier Scott- Boyer AU - Geeske M. van Woerden AU - Thomas Besnard AU - Jonas Johannes Papendorf AU - Maja Studencka-Turski AU - Tianyun Wang AU - Tzung-Chien Hsieh AU - Richard Golnik AU - Dustin Baldridge AU - Cara Forster AU - Charlotte de Konink AU - Selina M.W. Teurlings AU - Virginie Vignard AU - Richard H. van Jaarsveld AU - Lesley Ades AU - Benjamin Cogné AU - Cyril Mignot AU - Wallid Deb AU - Marjolijn C.J. Jongmans AU - F. Sessions Cole AU - Marie-José H. van den Boogaard AU - Jennifer A. Wambach AU - Daniel J. Wegner AU - Sandra Yang AU - Vickie Hannig AU - Jennifer Ann Brault AU - Neda Zadeh AU - Bruce Bennetts AU - Boris Keren AU - Anne-Claire Gélineau AU - Zöe Powis AU - Meghan Towne AU - Kristine Bachman AU - Andrea Seeley AU - Anita E. Beck AU - Jennifer Morrison AU - Rachel Westman AU - Kelly Averill AU - Theresa Brunet AU - Judith Haasters AU - Melissa T. Carter AU - Matthew Osmond AU - Patricia G. Wheeler AU - Francesca Forzano AU - Shehla Mohammed AU - Yannis Trakadis AU - Andrea Accogli AU - Rachel Harrison AU - Deciphering Developmental Disorders Study AU - Care4Rare Canada Consortium AU - Sophie Rondeau AU - Geneviève Baujat AU - Giulia Barcia AU - René Günther Feichtinger AU - Johannes Adalbert Mayr AU - Martin Preisel AU - Frédéric Laumonnier AU - Alexej Knaus AU - Bertrand Isidor AU - Peter Krawitz AU - Uwe Völker AU - Elke Hammer AU - Arnaud Droit AU - Evan E. Eichler AU - Ype Elgersma AU - Peter W. Hildebrand AU - François Bolduc AU - Elke Krüger AU - Stéphane Bézieau Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/07/2021.12.07.21266342.abstract N2 - A critical step in preserving protein homeostasis by the ubiquitin-proteasome system (UPS) is the recognition, binding, unfolding, and translocation of protein substrates by AAA-ATPase proteasome subunits for degradation by 26S proteasomes. Here, we identified fourteen different de novo missense variants in the PSMC3 gene encoding the AAA-ATPase proteasome subunit Rpt5 in twenty-two unrelated heterozygous subjects with an autosomal dominant form of neurodevelopmental delay and intellectual disability. Indeed, depletion of PSMC3 impaired reversal learning capabilities in a Drosophila model. The PSMC3 variants cause proteasome dysfunction in patient-derived cells by disruption of substrate translocation, proteotoxic stress and proteostatic imbalances, as well as alterations in proteins controlling developmental and innate immune programs. Molecular analysis confirmed the induction of cellular stress responses and dysregulated mitophagy along with an elevated type I interferon (IFN) signature. Our data define PSMC3 variants as the genetic cause of proteotoxic stress alerting the innate immune system to mount a type I IFN response and link neurodevelopmental syndromes to interferonopathies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German Research Foundation (SFBTR167, RGT2719-PRO project B4) to EK, E-Rare project GENOMIT (Austrian Science Fund FWF, I4695-B) to JAM, in part, by US National Institutes of Health (NIH) grants (R01MH101221) and a grant from the Simons Foundation (SFARI #608045) to E.E.E.; E.E.E. is an investigator of the Howard Hughes Medical Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the CHU de Nantes ethics committee (Medical Genetic Research Programme number DC-2011-1399).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -